Last Price$71.4(0.3%)
Market Cap$43.4B
LTM EBIT to Interest coverage
57.4x
5Y avg
158.1x
Medical - Devices industry
median
(7.0x)
Stock quality & Intrinsic value
6/10
(0.2%) overvalued
Edwards Lifesciences Corporation EBIT to Interest coverage
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBIT to Interest coverage | 18.1x | 0.0x | 0.0x | 27.5x | 216.4x | 118.5x | 96.8x | 92.8x | 87.4x | 44.7x | 69.1x | 93.3x | 352.7x | 25.0x | 55.4x | 103.1x | 73.3x | 91.1x | 87.2x | (0.0x) |
Overvalued or undervalued?
Check the intrinsic value for EW
and see if it's the right time to invest.
Edwards Lifesciences Corporation (EW) EBIT to Interest coverage comparison analysis
General
LTM EBIT to Interest coverage
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Edwards Lifesciences CorporationEW
57.4x
(9.4%)
202.2%
76.7%
Median Peer Set
8.9x
5.6%
72.0%
11.8%
Align Technology, Inc.ALGN
150.3x
3.4%
26.0%
11.5%
DexCom, Inc.DXCM
42.6x
11.3%
(1.4%)
14.3%
Abbott LaboratoriesABT
17.5x
4.6%
134.5%
31.9%
Boston Scientific CorporationBSX
9.3x
17.6%
16.7%
11.1%
STERIS plcSTE
9.1x
3.6%
257.9%
7.4%
Insulet CorporationPODD
8.7x
30.0%
4,364.6%
12.2%
Medtronic plcMDT
8.0x
3.6%
(2.1%)
11.4%
Zimmer Biomet Holdings, Inc.ZBH
6.0x
6.5%
253.2%
13.8%
Koninklijke Philips N.V.PHG
1.8x
(0.8%)
118.1%
(3.9%)
Stryker CorporationSYK
N/A
10.2%
(5.8%)
13.2%
EW key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 997.9 7.1% | 1,037.0 3.9% | 1,091.1 5.2% | 1,237.7 13.4% | 1,321.4 6.8% | 1,447.0 9.5% | 1,678.6 16.0% | 1,899.6 13.2% | 2,045.5 7.7% | 2,322.9 13.6% | 2,493.7 7.4% | 2,963.7 18.8% | 3,435.3 15.9% | 3,722.8 8.4% | 4,348.0 16.8% | 4,386.3 0.9% | 5,232.5 19.3% | 5,382.4 2.9% | 6,004.8 11.6% | 5,439.5 (9.4%) |
| Cost of Goods Sold (COGS) | 374.6 | 373.6 | 378.2 | 419.6 | 399.1 | 408.3 | 489.8 | 494.6 | 522.4 | 625.6 | 617.2 | 797.4 | 875.3 | 939.4 | 1,114.4 | 1,080.6 | 1,248.9 | 1,080.4 | 1,379.8 | 1,117.5 |
% margin | 623.3 62.5% | 663.4 64.0% | 712.9 65.3% | 818.1 66.1% | 922.3 69.8% | 1,038.7 71.8% | 1,188.8 70.8% | 1,405.0 74.0% | 1,523.1 74.5% | 1,697.3 73.1% | 1,876.5 75.2% | 2,166.3 73.1% | 2,560.0 74.5% | 2,783.4 74.8% | 3,233.6 74.4% | 3,305.7 75.4% | 3,983.6 76.1% | 4,302.0 79.9% | 4,625.0 77.0% | 4,322.0 79.5% |
| Operating Expenses | 447.7 | 490.2 | 540.3 | 643.8 | 684.3 | 754.4 | 888.7 | 996.6 | 1,068.6 | 1,204.5 | 1,233.8 | 1,348.0 | 1,537.3 | 1,710.7 | 1,994.9 | 1,989.1 | 2,396.8 | 2,512.8 | 3,090.9 | 2,842.2 |
| Research & Development Expenses (R&D) | 99.0 | 114.2 | 122.3 | 139.2 | 175.5 | 204.4 | 246.3 | 291.3 | 323.0 | 346.5 | 383.1 | 443.3 | 552.6 | 622.2 | 752.7 | 760.7 | 903.1 | 945.2 | 1,071.8 | 1,053.0 |
| Selling, General & Administrative Expenses (SG&A) | 348.7 | 376.0 | 418.0 | 480.6 | 508.8 | 550.0 | 642.4 | 705.3 | 745.6 | 858.0 | 850.7 | 904.7 | 984.7 | 1,088.5 | 1,242.2 | 1,228.4 | 1,493.7 | 1,567.6 | 1,824.6 | 1,789.2 |
% margin | 175.6 17.6% | 173.2 16.7% | 172.6 15.8% | 198.3 16.0% | 238.0 18.0% | 284.3 19.6% | 300.1 17.9% | 408.4 21.5% | 454.5 22.2% | 482.6 20.8% | 642.7 25.8% | 783.8 26.4% | 1,022.7 29.8% | 748.2 20.1% | 1,146.8 26.4% | 1,628.4 37.1% | 1,348.5 25.8% | 1,748.5 32.5% | 1,534.1 25.5% | (0.3) (0.0%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 6.1 | 1.6 | 0.9 | 3.4 | 0.4 | 4.6 | 6.4 | 7.9 | 10.8 | 20.3 | 32.0 | 11.5 | 23.4 | 17.4 | 35.5 | 67.2 | (120.3) |
| Interest Expense | 9.7 | 0.0 | 0.0 | 7.2 | 1.1 | 2.4 | 3.1 | 4.4 | 5.2 | 10.8 | 9.3 | 8.4 | 2.9 | 29.9 | 20.7 | 15.8 | 18.4 | 19.2 | 17.6 | 19.8 |
| Pre-tax Income | 116.7 | 172.3 | 149.8 | 164.4 | 304.4 | 268.2 | 283.6 | 391.1 | 515.3 | 1,144.0 | 622.4 | 737.9 | 1,034.9 | 761.4 | 1,166.5 | 916.7 | 1,702.0 | 1,767.4 | 1,598.1 | 1,548.1 |
% effective tax rate | 37.4 32.0% | 41.8 24.3% | 36.8 24.6% | 35.5 21.6% | 75.3 24.7% | 50.2 18.7% | 46.9 16.5% | 97.9 25.0% | 123.6 24.0% | 332.9 29.1% | 127.5 20.5% | 168.4 22.8% | 412.8 39.9% | 39.2 5.1% | 119.6 10.3% | 93.3 10.2% | 198.9 11.7% | 245.5 13.9% | 198.7 12.4% | 152.1 9.8% |
% margin | 79.3 7.9% | 130.5 12.6% | 113.0 10.4% | 128.9 10.4% | 229.1 17.3% | 218.0 15.1% | 236.7 14.1% | 293.2 15.4% | 391.7 19.1% | 811.1 34.9% | 494.9 19.8% | 569.5 19.2% | 622.1 18.1% | 722.2 19.4% | 1,046.9 24.1% | 823.4 18.8% | 1,503.1 28.7% | 1,521.9 28.3% | 1,402.4 23.4% | 4,174.6 76.7% |
| EPS | 0.11 | 0.19 | 0.16 | 0.19 | 0.34 | 0.32 | 0.35 | 0.43 | 0.59 | 1.27 | 0.77 | 0.89 | 0.98 | 1.15 | 1.68 | 1.32 | 2.41 | 2.46 | 2.31 | 6.98 |
| Diluted EPS | 0.11 | 0.18 | 0.16 | 0.18 | 0.33 | 0.31 | 0.33 | 0.41 | 0.57 | 1.25 | 0.75 | 0.87 | 0.96 | 1.13 | 1.64 | 1.30 | 2.38 | 2.44 | 2.30 | 6.97 |
% margin | 185.2 18.6% | 230.0 22.2% | 227.4 20.8% | 227.2 18.4% | 365.8 27.7% | 327.1 22.6% | 344.7 20.5% | 452.8 23.8% | 589.8 28.8% | 563.4 24.3% | 708.7 28.4% | 890.6 30.1% | 1,104.3 32.1% | 1,150.2 30.9% | 1,308.4 30.1% | 1,074.3 24.5% | 1,890.1 36.1% | 1,960.4 36.4% | 1,767.6 29.4% | (0.3) (0.0%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Edwards Lifesciences Corporation's EBIT to Interest coverage?
As of today, Microsoft Corp's last 12-month EBIT to Interest coverage is 57.4x, based on the financial report for Sep 30, 2024 (Q3’2024). The average annual EBIT to Interest coverage for Edwards Lifesciences Corporation have been 207.9x over the past three years, and 166.0x over the past five years.
2) Is Edwards Lifesciences Corporation's EBIT to Interest coverage Good?
As of today, Edwards Lifesciences Corporation's EBIT to Interest coverage is 57.4x, which is higher than industry median of (7.0x). It indicates that Edwards Lifesciences Corporation's EBIT to Interest coverage is Good.